Reuters logo
1 个月前
BRIEF-Aptevo Therapeutics' unit, CMC ICOS Biologics enter non-exclusive amended and restated commercial supply agreement
2017年6月22日 / 中午11点33分 / 1 个月前

BRIEF-Aptevo Therapeutics' unit, CMC ICOS Biologics enter non-exclusive amended and restated commercial supply agreement

2 分钟阅读

June 22 (Reuters) - Aptevo Therapeutics Inc

* Aptevo Therapeutics- on June 17, unit and CMC ICOS biologics entered non-exclusive amended and restated commercial supply agreement - SEC filing

* Aptevo -pursuant to terms of restated supply agreement, CMC agreed to manufacture product in quantity of batches provided to CMC on a 24 month rolling forecast

* Aptevo Therapeutics - restated supply deal supersedes, restates,replaces, as of restatement date, original supply agreement dated as of June 17, 2011

* Aptevo Therapeutics Inc says beginning 2018, batch minimum will be four batches and batch maximum will be ten batches in a calendar year

* Aptevo Therapeutics Inc says any batches ordered in a campaign should receive an incremental discounted price

* Aptevo Therapeutics Inc - in accordance with agreement, $7.0 million reserve held by CMC shall be applied to any batches manufactured through end of 2017

* Aptevo Therapeutics - in accordance with agreement, remaining amounts outstanding at year end shall be paid to Aptevo bio on or before Dec 31, 2017

* Aptevo Therapeutics Inc - On June 19, unit of co and Morphosys AG entered fourth amendment to license and co-development agreement

* Aptevo Therapeutics - pursuant to amendment, unit,Morphosys agreed Aptevo research and development continue to bear 75% of development costs with respect to MOR209/ES414 Source: (bit.ly/2rUDXSc) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below